Skip to main content
SpringerLink
Log in

Urokinase and Single-Chain Urokinase-Type Plasminogen Activator (Pro-urokinase)

  • Chapter
Book cover Fibrinolytics and Antifibrinolytics

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 146))

Abstract

The discovery of urokinase (UK) is described in chap. 4. The UK in urine is not a waste product as shown by studies of the fate of intravenous injections of UK, which was found not to be excreted by the kidney (Fletcher et al. 1965). Instead, it is secreted by renal tubular cells (Sappino et al. 1991) where it helps prevent obstruction of the tubules by fibrin and other proteinaceous deposits, as first proposed by Astrup and Sterndorff (1952). Kidney cells in culture are another current source of UK and Barlow and Lazer (1972) showed that UK from this source was identical to that purified from urine.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abercrombie DM, Buchinski B, Salvato KA, Vovis GF, Stump DC, Broeze RJ (1990) Fibrin specific thrombolysis by two-chain urokinase-type plasminogen activator cleaved after arginine 156 by thrombin. Thromb Haemost 64:426–432

    PubMed  CAS  Google Scholar 

  • Astrup T, Sterndorff I (1952) An activator of plasminogen in normal urine. Proc Soc Exp Biol Med 81:675–678

    PubMed  CAS  Google Scholar 

  • Badylak SF, Voytik S, Klabunde RE, Henkin J, Leski M (1988) Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis. Thromb Res 52:295–312

    Article  PubMed  CAS  Google Scholar 

  • Bär FW, Meyer J, Boland J, Betriu A, Artmeyer B, Charbonnier B, Michels HR, Tebbe U, Spiecker M, Vermeer F, von Fisenne MJ, Hopkins GR, Barth H (1998) Bolus Administration of Saruplase in Europe (BASE), a Pilot Study in Patients with Acute Myocardial Infarction. J Thromb Thrombolysis 6:147–153

    Article  PubMed  Google Scholar 

  • Bär FW, Meyer J, Vermeer F, Michels R, Charbonnier B, Haerten K, Spiecker M, Macaya C, Hanssen M, Heras M, Boland JP, Morice MC, Dunn FG, Uebis R, Hamm C, Ayzenberg O, Strupp G, Withagen AJ, Klein W, Windeler J, Hopkins G, Barth H, von Fisenne MJ, for the SESAM Study Group (1997) Comparison of saruplase and alteplase in acute myocardial infarction. Am J Cardiol 79:727–732

    Article  PubMed  Google Scholar 

  • Barlow GH, Francis CW, Marder VJ (1981) On the conversion of high molecular weight urokinase to the low molecular weight form by plasmin. Thromb Res 23:541–547

    Article  PubMed  CAS  Google Scholar 

  • Barlow GH, Lazer LA (1972) Characterization of the plasminogen activator isolated from human embryo kidney cells: comparison with urokinase. Thromb Haemost 1:201–208

    CAS  Google Scholar 

  • Bernik MB, Oller EP (1973) Increased plasminogen activator (urokinase) in tissue culture after fibrin deposition. J Clin Invest 42:823–834

    Article  Google Scholar 

  • Bernik MB, Oller EP (1976) Plasminogen activator and proactivator (urokinase precursor) in lung cultures. J Am Med Wom Assoc 31:465–472

    PubMed  CAS  Google Scholar 

  • Bode C, Matsueda GR, Hui KY, Haber E (1990a) Antibody-directed urokinase: a specific fibrinolytic agent. Science 229:765–767

    Article  Google Scholar 

  • Bode C, Runge MS, Newell JB, Matsueda GR, Haber E (1987) Characterization of an antibody-urokinase conjugate. A plasminogen activator targeted to fibrin. J Biol Chem 262:10819–10823

    PubMed  CAS  Google Scholar 

  • Bode C, Runge MS, Schönermark S, Eberle T, Newell JB, Küber W, Haber E (1990b) Conjugation to antifibrin Fab’ enhances fibrinolytic potency of single-chain urokinase plasminogen activator. Circulation 81:1974–1980

    Article  PubMed  CAS  Google Scholar 

  • Bode C, Schoenermark S, Schuler G, Zimmermann R, Schwarz F, Kuebler W (1988) Efficacy of intravenous prourokinase and a combination of prourokinase and urokinase in acute myocardial infarction. Am J Cardiol 61:971–974

    Article  PubMed  CAS  Google Scholar 

  • Bode C, Schuler G, Nordt T, Schönermark S, Baumann H, Richardt G, Dietz R, Gurewich V, Kübler W (1990c) Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction. Circulation 81:907–913

    Article  PubMed  CAS  Google Scholar 

  • Braat EAM, Levi M, Bos R, Haverkate F, Lassen MR, de Maat MPM, Rijken DC (1999) Inactivation of single-chain urokinase-type plasminogen activator by thrombin in human subjects. J Lab Clin Med 134:161–167

    Article  PubMed  CAS  Google Scholar 

  • Braat EAM, Los P, Rijken DC (1998) The inactivation of single-chain urokinase-type plasminogen activator by thrombin in a plasma milieu: effect of thrombomodulin. Blood Coagul Fibrinolysis 9:419–427

    Article  PubMed  CAS  Google Scholar 

  • Breton J, Pezzi N, Molinari A, Bonomini L, Lansen J, Gonzalez De Buitrago G, Prieto I (1995) Prolonged half-life in the circulation of a chemical conjugate between a pro-urokinase derivative and human serum albumin. Eur J Biochem 231:563–569

    Article  PubMed  CAS  Google Scholar 

  • Brochier M, Raynaud R, Planiol T, Fauchier JP, Griguer P, Archambaud D, Pellois A, Clisson M (1975) Le traitement par l’urokinase des infarctus du myocarde et syndromes de menace. Arch Mal Coeur Vaiss 68:563–569

    PubMed  CAS  Google Scholar 

  • Carlsson J, Schuster HP, Tebbe U (1997) Prähospitale thrombolytische Therapie bei akutem Myokardinfarkt. Anaesthesist 46:829–839

    Article  PubMed  CAS  Google Scholar 

  • Collen D (1985) Report of the Meeting of the Subcommittee on Fibrinolysis, San Diego, CA. Thromb Haemost 54:893

    Google Scholar 

  • Collen D, De Cock F, Demarsin E, Lijnen HR, Stump DC (1986a) Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinasetype plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro. Thromb Haemost 56:35–39

    PubMed  CAS  Google Scholar 

  • Collen D, Stassen J-M, De Cock F (1987) Synergistic effect of thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA), single chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model. Thromb Haemost 58:943–946

    PubMed  CAS  Google Scholar 

  • Collen D, Stassen JM, Blaber M, Winkler M, Verstraete M (1984) Biological and thrombolytic properties of proenzyme and active forms of human urokinase. 3. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis. Thromb Haemost 52:27–30

    PubMed  CAS  Google Scholar 

  • Collen D, Stump D, Van de Werf F (1985) Coronary thrombolysis in dogs with intravenously administered pro-urokinase. Circulation 72:384–388

    Article  PubMed  CAS  Google Scholar 

  • Collen D, Van de Werf F (1987) Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction. Am J Cardiol 60:431–434

    Article  PubMed  CAS  Google Scholar 

  • Collen D, Zamarron C, Lijnen HR, Hoylaerts M (1986b) Activation of plasminogen by pro-urokinase. 2. Kinetics. J Biol Chem 261:1259–1266

    PubMed  CAS  Google Scholar 

  • de Boer A, Kluft C, Gerloff J, Dooijewaard G, Günzler WA, Beier H, van der Meer FJM, Cohen AF (1993) Pharmacokinetics of saruplase, a recombinant unglycosylated human single-chain urokinase-type plasminogen activator and its effects on fibrinolytic and haemostatic parameters in healthy male subjects. Thromb Haemost 70:320–325

    PubMed  Google Scholar 

  • de Munk GAW, Groeneveld E, Rijken DC (1991) Acceleration of the thrombin inactivation of single chain urokinase-type plasminogen activator (pro-urokinase) by thrombomodulin. J Clin Invest 88:1680–1684

    Article  PubMed  Google Scholar 

  • de Prost D, Guerot C, Laffay N, Horellou MH, Samama M (1983) Intra-coronary thrombolysis with streptokinase or lys-plasminogen/urokinase in acute myocardial infarction: effects on recanalization and blood fibrinolysis. Thromb Haemost 50:792–796

    PubMed  Google Scholar 

  • Declerck PJ, Lijnen HR, Verstreken M, Moreau H, Collen D (1990) A monoclonal antibody specific for two-chain urokinase-type plasminogen activator. Application to the study of the mechanism of clot lysis with single-chain urokinase-type plasminogen activator in plasma. Blood 75:1794–1800

    PubMed  CAS  Google Scholar 

  • Diefenbach C (1992) One-year follow-up in a randomized double-blind trial of saruplase versus streptokinase in acute myocardial infarction: Long-term results of the PRIMI trial. Coron Artery Dis 3:925–931

    Google Scholar 

  • Diefenbach C, Erbel R, Pop T, Mathey D, Schofer J, Hamm C, Ostermann H, Schmitz Hubner U, Bleifeld W, Meyer J (1988) Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction. Am J Cardiol 61:966–970

    Article  PubMed  CAS  Google Scholar 

  • Eguchi Y, Sakata Y, Matsuda M, Osada H, Numao N, Ohmori M, Kondo K (1990) Characterization of thrombin-and plasmin-resistant mutants of recombinant human single chain urokinase-type plasminogen activator. J Biochem (Tokyo) 108:72–79

    CAS  Google Scholar 

  • European Collaborative Study (1975) Controlled trial of urokinase in myocardial infarction. Lancet 2:624–627

    Google Scholar 

  • Fay WP, Eitzman DT, Shapiro AD, Madison EL, Ginsburg D (1994) Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and-independent mechanisms. Blood 83:351–356

    PubMed  CAS  Google Scholar 

  • Ferguson JJ (1999) Highlights of the 20th Congress of the European Society of Cardiology. Circulation 99:1127–1131

    Article  PubMed  CAS  Google Scholar 

  • Flameng W, Vanhaecke J, Stump DC, Van de Werf F, Holmes W, Guenzler WA, Flohe L, Collen D (1986) Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis. J Am Coll Cardiol 8:118–124

    Article  PubMed  CAS  Google Scholar 

  • Fletcher AP, Alkjaersig N, Sherry S, Genton E, Hirsh J, Bachmann F (1965) The development of urokinase as a thrombolytic agent: maintenance of a sustained thrombolytic state in man by its intravenous infusion. J Lab Clin Med 65:713–731

    PubMed  CAS  Google Scholar 

  • Fry ET, Mack DL, Sobel BE (1989) The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators. Thromb Haemost 62:909–916

    PubMed  CAS  Google Scholar 

  • Gormsen J, Tidstrom B, Feddersen C, Ploug J (1973) Biochemical evaluation of low dose of urokinase in acute myocardial infarction. A double-blind study. Acta Med Scand 194:191–198

    Article  PubMed  CAS  Google Scholar 

  • Gulba DC, Fischer K, Barthels M, Jost S, Möller W, Frombach R, Reil G-H, Daniel WG, Lichtlen PR (1989a) Potentiative effect of heparin in thrombolytic therapy of evolving myocardial infarction with natural pro-urokinase. Fibrinolysis 3:165–173

    Google Scholar 

  • Gulba DCL, Fischer K, Barthels M, Polensky U, Reil G-H, Daniel WG, Welzel D, Lichtlen PR (1989b) Low dose urokinase preactivated natural prourokinase for thrombolysis in acute myocardial infarction. Am J Cardiol 63:1025–1031

    Article  PubMed  CAS  Google Scholar 

  • Gurewich V (1987) Experiences with pro-urokinase and potentiation of its fibrinolytic effect by urokinase and by tissue plasminogen activator. J Am Coll Cardiol 10:16B–121

    Article  PubMed  CAS  Google Scholar 

  • Gurewich V (1989a) Importance of fibrin specificity in therapeutic thrombolysis and the rationale of using sequential and synergistic combinations of tissue plasminogen activator and pro-urokinase. Semin Thromb Hemost 15:123–128

    Article  PubMed  CAS  Google Scholar 

  • Gurewich V (1989b) The sequential, complementary and synergistic activation of fibrin-bound plasminogen by tissue plasminogen activator and pro-urokinase. Fibrinolysis 3:59–66

    CAS  Google Scholar 

  • Gurewich V, Emmons F, Pannell R (1988a) Spontaneous clot lysis in whole human plasma by endogenous tissue type and urokinase type plasminogen activators: demonstration of a promoting effect by t-PA and by platelets on urokinase. Fibrinolysis 2:143–149

    CAS  Google Scholar 

  • Gurewich V, Johnstone M, Loza J-P, Pannell R (1993) Pro-urokinase and prekallikrein are both associated with platelets: Implications for the intrinsic pathway of fibrinolysis and for therapeutic thrombolysis. FEBS Lett 318:317–321

    Article  PubMed  CAS  Google Scholar 

  • Gurewich V, Johnstone MT, Pannell R (1995) The selective uptake of high molecular weight urokinase-type plasminogen activator by human platelets. Fibrinolysis 9:188–195

    CAS  Google Scholar 

  • Gurewich V, Muller J (1996) Is coronary thrombolysis associated with side effects that significantly compromise clinical benefits. Am J Cardiol 77:756–758

    Article  PubMed  CAS  Google Scholar 

  • Gurewich V, Pannell R (1986) A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity. Thromb Res 44:217–228

    Article  PubMed  CAS  Google Scholar 

  • Gurewich V, Pannell R (1987) Inactivation of single-chain urokinase (pro-urokinase) by thrombin and thrombin-like enzymes: relevance of the findings to the interpretation of fibrin-binding experiments. Blood 69:769–772

    PubMed  CAS  Google Scholar 

  • Gurewich V, Pannell R, Broeze RJ, Mao J (1988b) Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine158. J Clin Invest 82:1956–1962

    Article  PubMed  CAS  Google Scholar 

  • Gurewich V, Pannell R, Louie S, Kelley P, Suddith L, Greenlee R (1984) Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase): A study in vitro and in two animal species. J Clin Invest 73:1731–1739

    Article  PubMed  CAS  Google Scholar 

  • Harpel PC, Chang T, Verderber E (1985) Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin I. J Biol Chem 260:4432–4440

    PubMed  CAS  Google Scholar 

  • Hauert J, Nicoloso G, Schleuning WD, Bachmann F, Schapira M (1989) Plasminogen activators in dextran sulfate-activated euglobulin fractions: a molecular analysis of factor XII-and prekallikrein-dependent fibrinolysis. Blood 73:994–999

    PubMed  CAS  Google Scholar 

  • Hiramatsu R, Kasai S, Amatsuji Y, Kawai T, Hirose M, Morita M, Tanabe T, Kawabe H, Arimura H, Yokoyama K (1989) Effect of deletion of epidermal growth factor-like domain on plasma clearance of pro-urokinase. Fibrinolysis 3:147–151

    CAS  Google Scholar 

  • Hua Z-C, Chen X-C, Dong C, Zhu D-X (1996) Characterization of a recombinant chimeric plasminogen activator composed of Gly-Pro-Arg-Pro tetrapeptide and truncated urokinase-type plasminogen activator expressed in Escherichia coli. Biochem Biophys Res Commun 222:576–583

    Article  PubMed  CAS  Google Scholar 

  • Husain SS (1991) Single-chain urokinase-type plasminogen activator does not possess measurable intrinsic amidolytic or plasminogen activator activities. Biochemistry 30:5797–5805

    Article  PubMed  CAS  Google Scholar 

  • Husain SS (1993) Fibrin affinity of urokinase-type plasminogen activator. Evidence that Zn2+ mediates strong and specific interaction of single-chain urokinase with fibrin. J Biol Chem 268:8574–8579

    PubMed  CAS  Google Scholar 

  • Husain SS, Gurewich V, Lipinski B (1983) Purification and partial characterization of a single-chain molecular weight form of urokinase from human urine. Arch Biochem Biophys 220:31–38

    Article  PubMed  CAS  Google Scholar 

  • Husain SS, Lipinski B, Gurewich V (1979) Isolation of plasminogen activators useful as therapeutic and diagnostic agents (single-chain, high-affinity urokinase). US Patent 4:381–346

    Google Scholar 

  • Ichinose A, Fujikawa K, Suyama T (1986) The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 261:3486–3489

    PubMed  CAS  Google Scholar 

  • Jiang YP, Pannell R, Liu JN, Gurewich V (1996) Evidence for a novel binding protein to urokinase-type plasminogen activator in platelet membranes. Blood 87:2775–2781

    PubMed  CAS  Google Scholar 

  • Kajihara J, Shibata K, Nakano Y, Nishimuro S, Kato K (1994) Physicochemical characterization of PEG-PPG conjugated human urokinase. Biochim Biophys Acta Gen Subj 1199:202–208

    Article  CAS  Google Scholar 

  • Kambara H, Kawai C, Kajiwara N, Niitani H, Sasayama S, Kanmatsuse K, Kodama K, Sato H, Nobuyoshi M, Nakashima M, Matsuo O, Matsuda T (1988) Randomized, double-blinded multicenter study. Comparison of intracoronary single-chain urokinase-type plasminogen activator, pro-urokinase (GE-0943), and intracoronary urokinase in patients with acute myocardial infarction. Circulation 78:899–905

    Article  PubMed  CAS  Google Scholar 

  • Kanemoto N, Goto Y, Hirosawa K, Kawai C, Kimata S, Yui Y, Yamamoto Y (1991) Intravenous recombinant tissue-type plasminogen activator (rt-PA) and urokinase (UK) in patients with evolving myocardial infarction — A multicenter doubleblind, randomized trial in Japan. Jpn Circ J 55(3):250–261

    Article  PubMed  CAS  Google Scholar 

  • Kirshenbaum JM, Bahr RD, Flaherty JT, Gurewich V, Levine HJ, Loscalzo J, Schumacher RR, Topol EJ, Wahr DW, Braunwald E, for the Pro-Urokinase for Myocardial Infarction Study Group (1991) Clot-selective coronary thrombolysis with low-dose synergistic combinations of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator. Am J Cardiol 68:1564–1569

    Article  PubMed  CAS  Google Scholar 

  • Klein P (1989) Plasma levels of t-PA:AG under standard heparin therapy. Thromb Res 56:649–653

    Article  PubMed  CAS  Google Scholar 

  • Kono T, Morita H, Nishina T, Fujita M, Hirota Y, Kawamura K, Fujiwara A (1996) Circadian variations of onset of acute myocardial infarction and efficacy of thrombolytic therapy. J Am Coll Cardiol 27:774–778

    Article  PubMed  CAS  Google Scholar 

  • Koster RW, Cohen AF, Hopkins GR, Beier H, Günzler WA, van der Wouw PA (1994) Pharmacokinetics and pharmacodynamics of Saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Thromb Haemost 72:740–744

    PubMed  CAS  Google Scholar 

  • Kurnik PB (1995) Circadian variation in the efficacy of tissue-type plasminogen activator. Circulation 91:1341–1346

    Article  PubMed  CAS  Google Scholar 

  • Köhler M, Sen S, Miyashita C, Hermes R, Pindur G, Heiden M, Berg G, Mörsdorf S, Leipnitz G, Zeppezauer M, Schieffer H, Wenzel E, Schönberger A, Hollemeyer K (1991) Half-life of single-chain urokinase-type plasminogen activator (scu-PA) and two-chain urokinase-type plasminogen activator (tcu-PA) in patients with acute myocardial infarction. Thromb Res 62:75–81

    Article  PubMed  Google Scholar 

  • Lang IM, Marsh JJ, Konopka RG, Olman MA, Binder BR, Moser KM, Schleef RR (1993) Factors contributing to increased vascular fibrinolytic activity in mongrel dogs. Circulation 87:1990–2000

    Article  PubMed  CAS  Google Scholar 

  • Lenich C, Pannell R, Henkin J, Gurewich V (1992) The influence of glycosylation on the catalytic and fibrinolytic properties of pro-urokinase. Thromb Haemost 68:539–544

    PubMed  CAS  Google Scholar 

  • Li C, Jiang Y, Gurewich V, Liu JN (1996) Urokinase-type plasminogen activator (u-PA) stimulates its own expression in endothelial cells and monocytes. Fibrinolysis 10:257 (abstr)

    Google Scholar 

  • Li X-K, Lijnen HR, Nelles L, Hu M-H, Collen D (1992) Biochemical properties of recombinant mutants of nonglycosylated single chain urokinase-type plasminogen activator. Biochim Biophys Acta Protein Struct Mol Enzymol 1159:37–43

    Article  CAS  Google Scholar 

  • Lieber A, Peeters MJ, Gown A, Perkins J, Kay MA (1995) A modified urokinase plasminogen activator induces liver regeneration without bleeding. Hum Gene Ther 6:1029–1037

    Article  PubMed  CAS  Google Scholar 

  • Lijnen HR, Nelles L, Van Houtte E, Collen D (1990) Pharmacokinetic properties of mutants of recombinant single chain urokinase-type plasminogen activator obtained by site-specific mutagenesis of Lys158, Ile159 and Ile160. Fibrinolysis 4:211–214

    CAS  Google Scholar 

  • Lijnen HR, Pierard L, Reff ME, Gheysen D (1988a) Characterization of a chimaeric plasminogen activator obtained by insertion of the second kringle structure of tissue-type plasminogen activator (amino acids 173 through 262) between residues Asp 130 and Ser 139 of urokinase-type plasminogen activator. Thromb Res 52:431–441

    Article  PubMed  CAS  Google Scholar 

  • Lijnen HR, Van Hoef B, Nelles L, Holmes WE, Collen D (1988b) Enzymatic properties of single-chain and two-chain forms of a Lys158®Glu158 mutant of urokinase-type plasminogen activator. Eur J Biochem 172:185–188

    Article  PubMed  CAS  Google Scholar 

  • Lippschutz EJ, Ambrus JL, Ambrus CM, et al (1965) Controlled study on the treatment of coronary occlusion with urokinase-activated human plasmin. Am J Cardiol 16:93–98

    Article  Google Scholar 

  • Liu JN, Gurewich V (1991) A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin. J Clin Invest 88:2012–2017

    Article  PubMed  CAS  Google Scholar 

  • Liu JN, Gurewich V (1992) Fragment E-2 from fibrin substantially enhances prourokinase-induced Glu-plasminogen activation. A kinetic study using the plasmin-resistant mutant pro-urokinase Ala-158-rpro-UK. Biochemistry 31:6311–6317

    Article  PubMed  CAS  Google Scholar 

  • Liu JN, Gurewich V (1993) The kinetics of plasminogen activation by thrombin-cleaved pro-urokinase and promotion of its activity by fibrin fragment E-2 and by tissue plasminogen activator. Blood 81:980–987 Liu JN, Gurewich V (1995) Inactivation of the intrinsic activity of pro-urokinase by diisopropyl fluorophosphate is reversible. J Biol Chem 270:8408–8410

    PubMed  CAS  Google Scholar 

  • Liu JN, Pannell R, Gurewich V (1992) A transitional state of pro-urokinase that has a higher catalytic efficiency against glu-plasminogen than urokinase. J Biol Chem 267:15289–15292

    PubMed  CAS  Google Scholar 

  • Liu JN, Tang W, Sun ZY, Kung W, Pannell R, Sarmientos P, Gurewich V (1996) A site-directed mutagenesis of pro-urokinase which substantially reduces its intrinsic activity. Biochemistry 35:14070–14076

    Article  PubMed  CAS  Google Scholar 

  • Loscalzo J, Wharton TP, Kirshenbaum JM, Levine HJ, Flaherty JT, Topol EJ, Ramaswamy K, Kosowsky BD, Salem DN, Ganz P, et al (1989) Clot-selective coronary thrombolysis with pro-urokinase. Circulation 79:776–782

    Article  PubMed  CAS  Google Scholar 

  • Loza J-P, Gurewich V, Johnstone M, Pannell R (1994) Platelet-bound prekallikrein promotes pro-urokinase-induced clot lysis: a mechanism for targeting the factor XII dependent intrinsic pathway of fibrinolysis. Thromb Haemost 71:347–352

    PubMed  CAS  Google Scholar 

  • Ma Z, Yu RR, Hua ZC, Zhu DX (1996) Urokinase mutant with better fibrin-specificity. Science in China 39:523–533

    PubMed  CAS  Google Scholar 

  • Manchanda N, Schwartz BS (1991) Single chain urokinase. Augmentation of enzymatic activity upon binding to monocytes. J Biol Chem 266:14580–14584

    PubMed  CAS  Google Scholar 

  • Mathey DG, Schofer J, Sheehan FH, Becher H, Tilsner V, Dodge HT (1985) Intravenous urokinase in acute myocardial infarction. Am J Cardiol 55:878–882

    Article  PubMed  CAS  Google Scholar 

  • Michels HR, Hoffman JJ, Bär FW (1999) Pharmacokinetics and hemostatic effects of saruplase in patients with acute myocardial infarction: comparison of infusion, single-bolus, and split-bolus administration. J Thromb Thrombolysis 8:213–221

    Article  PubMed  CAS  Google Scholar 

  • Michels R, Hoffmann H, Windeler J, et al. (1995) A double-blind multicenter comparison of the efficacy and safety of Saruplase and urokinase in the treatment of acute myocardial infarction: report of the SUTAMI Study Group. J Thrombos Thrombolys 2:117–124

    Article  CAS  Google Scholar 

  • Miles LA, Plow EF (1985) Binding and activation of plasminogen on the platelet surface. J Biol Chem 260:4303–4311

    PubMed  CAS  Google Scholar 

  • Muller JE, Stone PH, Turi ZG, Rutherford JD, Czeisler CA, Parker C, Poole WK, Passamini E, Roberts R, Robertson T, Sobel BE, Willerson JT, Braunwald E, and the MILIS Study Group (1985) Circadian variation in the frequency of onset of acute myocardial infarction. N Engl J Med 313:1315–1322

    Article  PubMed  CAS  Google Scholar 

  • Nelles L, Lijnen HR, Van Nuffelen A, Demarsin E, Collen D (1990) Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA). Thromb Haemost 64:53–60

    PubMed  CAS  Google Scholar 

  • Neuhaus KL, Tebbe U, Gottwik M, Weber MAJ, Feuerer W, Niederer W, Haerer W, Praetorius F, Grosser KD, Huhmann W, Hoepp HW, Alber G, Sheikhzadeh A, Schneider B (1988) Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS). J Am Coll Cardiol 12:581–587

    Article  PubMed  CAS  Google Scholar 

  • Nguyen G, Fretault J, Samama M, Coursaget J (1989) Thrombolytic properties of tissue plasminogen activator (t-PA) and single chain urokinase plasminogen activator (scu-PA) in vitro: absence of synergy as demonstrated by two quantitative analytical methods. Fibrinolysis 3:23–26

    CAS  Google Scholar 

  • Nielsen LS, Hansen JG, Skriver L, Wilson EL, Kaltaft K, Zeuthen J, Danø K (1982) Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry 21:6410–6415

    Article  PubMed  CAS  Google Scholar 

  • Nieuwenhuizen W, Vermond A, Voskuilen M, Traas DW, Verheijen JH (1983) Identification of a site in fibrin(ogen) which is involved in the acceleration of plasminogen activation by tissue-type plasminogen activator. Biochim Biophys Acta 748:86–92

    Article  PubMed  CAS  Google Scholar 

  • Nolan C, Hall LS, Barlow GH, Tribby II (1977) Plasminogen activator from human embryonic kidney cell cultures. Evidence for a proactivator. Biochim Biophys Acta 496:384–400

    Article  PubMed  CAS  Google Scholar 

  • Pannell R, Black J, Gurewich V (1988) Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained. J Clin Invest 81:853–859

    Article  PubMed  CAS  Google Scholar 

  • Pannell R, Gurewich V (1986) Pro-urokinase: a study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood 67:1215–1223

    PubMed  CAS  Google Scholar 

  • Pannell R, Gurewich V (1987) Activation of plasminogen by single-chain urokinase or by two-chain urokinase — A demonstration that single-chain urokinase has a low catalytic activity (pro-urokinase). Blood 69:22–26

    PubMed  CAS  Google Scholar 

  • Park S, Harker LA, Marzec UM, Levin EG (1989) Demonstration of single chain urokinase-type plasminogen activator on human platelet membrane. Blood 73:1421–1425

    PubMed  CAS  Google Scholar 

  • Park SJ, for the Thrombolysis in Myocardial Infarction in Korea (TIMIKO) Study Group (1998) Comparison of double bolus urokinase versus front-loaded alteplase regimen for acute myocardial infarction. Am J Cardiol 82:811–813

    Article  PubMed  CAS  Google Scholar 

  • Petersen LC, Lund LR, Nielsen LS, Danø K, Skriver L (1988) One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J Biol Chem 263:11189–11195

    PubMed  CAS  Google Scholar 

  • PRIMI Trial Study Group, Meyer J, Bär F, Barth H, Charbonnier B, El Deeb MF, Erbel R, Flohé L, Gülker H, Heikkilä J, Massberg I (1989) Randomised double-blind trial of recombinant pro-urokinase against streptokinase acute myocardial infarction. Lancet i:863–867

    Google Scholar 

  • Pâques E-P, Karges H-E, Römisch J (1992) Prevention of fibrinogenolysis without impairment of thrombolysis: combination of a plasminogen activator with α2-antiplasmin. Fibrinolysis 6:111–117

    Google Scholar 

  • Rossi P, Bolognese L (1991) Comparison of intravenous urokinase plus heparin versus heparin alone in acute myocardial infarction. Am J Cardiol 68:585–592

    Article  PubMed  CAS  Google Scholar 

  • Runge MS, Harker LA, Bode C, Ruef J, Kelly AB, Marzec UM, Allen E, Caban R, Shaw S-Y, Haber E, Hanson SR (1996) Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons. Circulation 94:1412–1422

    Article  PubMed  CAS  Google Scholar 

  • Sabovic M, Keber D (1995) In-vitro synergism between t-PA and scu-PA depends on clot retraction. Fibrinolysis 9:101–105

    CAS  Google Scholar 

  • Sakuragawa N, Shimizu K, Kondo K, Kondo S, Niwa M (1986) Studies on the effect of PEG-modified urokinase on coagulation-fibrinolysis using beagles. Thromb Res 41:627–635

    Article  PubMed  CAS  Google Scholar 

  • Sappino A-P, Huarte J, Vassalli J-D, Belin D (1991) Sites of synthesis of urokinase and tissue-type plasminogen activators in the murine kidney. J Clin Invest 87:962–970

    Article  PubMed  CAS  Google Scholar 

  • Sasaki K, Moriyama S, Tanaka Y, Sumi H, Robbins KC (1985) The transport of 125I-labeled human high molecular weight urokinase across the intestinal tract in a dog model with stimulation of synthesis and/or release of plasminogen activators. Blood 66:69–75

    PubMed  CAS  Google Scholar 

  • Schneider P, Bachmann F, Sauser D (1982) Urokinase. A short review of its properties and of its metabolism. In: Mannucci PM, D’Angelo A (eds) Urokinase: basic and clinical aspects. Academic Press, London, pp 1–15

    Google Scholar 

  • Schofer J, Büttner J, Geng G, Gutschmidt K, Herden HN, Mathey DG, Moecke HP, Polster P, Raftopoulo A, Sheehan FH, Voelz P (1990) Prehospital thrombolysis in acute myocardial infarction. Am J Cardiol 66:1429–1433

    Article  PubMed  CAS  Google Scholar 

  • Sobel GW, Mohler SR, Jones NW, Dowdy ABC, Guest MM (1952) Urokinase: an activator of plasma profibrinolysin extracted from human urine. Am J Physiol 171:768–769

    Google Scholar 

  • Spiecker M, Windeler J, Vermeer F, Michels R, Seabra-Gomes R, vom Dahl J, Kerber S, Verheugt FWA, Westerhof PW, Bär FW, Nixdorff U, Barth H, Hopkins GR, von Fisenne MJM, Meyer J, for the PRIMI Investigators (1999) Thrombolysis with saruplase versus streptokinase in acute myocardial infarction: five-year results of the PRIMI trial. Am Heart J 138:518–524

    Article  PubMed  CAS  Google Scholar 

  • Stump DC, Kieckens L, De Cock F, Collen D (1987) Pharmacokinetics of single chain forms of urokinase-type plasminogen activator. J Pharmacol Exp Ther 242:245–250

    PubMed  CAS  Google Scholar 

  • Stump DC, Thienpont M, Collen D (1986) Urokinase-related proteins in human urine. Isolation and characterization of single-chain urokinase (pro-urokinase) and urokinase-inhibitor complex. J Biol Chem 261:1267–1273

    PubMed  CAS  Google Scholar 

  • Suenson E, Bjerrum P, Holm A, Lind B, Meldal M, Selmer J, Petersen LC (1990) The role of fragment X polymers in the fibrin enhancement of tissue plasminogen activator-catalyzed plasmin formation. J Biol Chem 265:22228–22237

    PubMed  CAS  Google Scholar 

  • Sumi H, Sasaki K, Toki N, Robbins KC (1980) Oral administration of urokinase. Thromb Res 20:711–714

    Article  PubMed  CAS  Google Scholar 

  • Sumi H, Seiki M, Morimoto N, Tsushima H, Maruyama M, Mihara H (1985) Plasma fibrinolysis after intraduodenal administration of urokinase in rats. Enzyme 33:122–127

    PubMed  CAS  Google Scholar 

  • Sun Z, Jiang Y, Ma Z, Wu H, Liu BF, Xue Y, Tang W, Chen Y, Li C, Zhu D, Gurewich V, Liu JN (1997) Identification of a flexible loop region (297–313) of urokinase-type plasminogen activator, which helps determine its catalytic activity. J Biol Chem 272:23818–23823

    Article  PubMed  CAS  Google Scholar 

  • Tebbe U, Michels R, Adgey J, Boland J, Caspi A, Charbonnier B, Windeler J, Barth H, Groves R, Hopkins GR, Fennell W, Betriu A, Ruda M, Mlczoch J, for the Comparison Trial of Saruplase and Streptokinase (COMPASS) Investigators (1998) Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS Equivalence Trial. J Am Coll Cardiol 31:487–493

    Article  PubMed  CAS  Google Scholar 

  • Tebbe U, Windeler J, Boesl I, Hoffmann H, Wojcik J, Ashmawy M, Schwarz ER, von Loewis of Menar P, Rosemeyer P, Hopkins G, Barth H, on behalf of the LIMITS Study Group (1995) Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). J Am Coll Cardiol 26:365–373

    Article  PubMed  CAS  Google Scholar 

  • The GUSTO Investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329:673–682

    Article  Google Scholar 

  • Tissot J-D, Schneider P, Hauert J, Ruegg M, Kruithof EKO, Bachmann F (1982) Isolation from human plasma of plasminogen activator identical to urinary high molecular weight urokinase. J Clin Invest 70:1320–1323

    Article  PubMed  CAS  Google Scholar 

  • Toki N, Sumi H, Sasaki K, Boreisha I, Robbins KC (1985) Transport of urokinase across the intestinal tract of normal human subjects with stimulation of synthesis and/or release of urokinase-type proteins. J Clin Invest 75:1212–1222

    Article  PubMed  CAS  Google Scholar 

  • Topol EJ, Califf RM, George BS, Kereiakes DJ, Rothbaum D, Candela RJ, Abbotsmith CW, Pinkerton CA, Stump DC, Collen D, Lee KL, Pitt B, Kline EM, Boswick JM, O’Neill WW, Stack RS, and the TAMI Study Group (1988) Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. Circulation 77:1100–1107

    Article  PubMed  CAS  Google Scholar 

  • Torr SR, Nachowiak DA, Fujii S, Sobel BE (1992) “Plasminogen steal” and clot lysis. J Am Coll Cardiol 19:1085–1090

    Article  PubMed  CAS  Google Scholar 

  • Tran-Thang Ch, Kruithof EKO, Atkinson J, Bachmann F (1986) High-affinity binding sites for human Glu-plasminogen unveiled by limited plasmic degradation of human fibrin. Eur J Biochem 160:599–604

    Article  PubMed  CAS  Google Scholar 

  • Van de Werf F, Nobuhara M, Collen D (1986a) Coronary thrombolysis with human single-chain, urokinase-type plasminogen activator (pro-urokinase) in patients with acute myocardial infarction. Ann Intern Med 104:345–348

    PubMed  Google Scholar 

  • Van de Werf F, Vanhaecke J, De Geest H, Verstraete M, Collen D (1986b) Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction. Circulation 74:1066–1070

    Article  PubMed  Google Scholar 

  • Van Griensven JMT, Koster RW, Hopkins GR, Beier H, Günzler WA, Kroon R, Schoemaker RC, Cohen AF (1997) Effect of changes in liver blood flow on the pharmacokinetics of saruplase in patients with acute myocardial infarction. Thromb Haemost 78:1015–1020

    PubMed  Google Scholar 

  • Váradi A, Patthy L (1983) Location of plasminogen-binding sites in human fibrin(ogen). Biochemistry 22:2440–2446

    Article  PubMed  Google Scholar 

  • Vermeer F, Bosl I, Meyer J, Bär F, Charbonnier B, Windeler J, Barth H (1999) Saruplase is a safe and effective thrombolytic agent; observations in 1,698 patients. Results of the PASS study. Practical Applications of Saruplase Study. J Thrombos Thrombolys 8:143–150

    Article  CAS  Google Scholar 

  • Wall TC, Phillips HR,III, Stack RS, Mantell S, Aronson L, Boswick J, Sigmon K, DiMeo M, Chaplin D, Whitcomb D, Pasi D, Zawodniak M, Hajisheik M, Hegde S, Barker W, Tenney R, Califf RM (1990) Results of high dose intravenous urokinase for acute myocardial infarction. Am J Cardiol 65:124–131

    Article  PubMed  CAS  Google Scholar 

  • Weaver WD, Hartmann JR, Anderson JL, Reddy PS, Sobolski JC, Sasahara AA (1994) New recombinant glycosylated prourokinase for treatment of patients with acute myocardial infarction. J Am Coll Cardiol 24:1242–1248

    Article  PubMed  CAS  Google Scholar 

  • Wohn KD, Kanse SM, Deutsch V, Schmidt T, Eldor A, Preissner KT (1997) The urokinase-receptor (CD87) is expressed in cells of the megakaryoblastic lineage. Thromb Haemost 77:540–547

    PubMed  CAS  Google Scholar 

  • Wun TC, Ossowski L, Reich E (1982a) A proenzyme of human urokinase. J Biol Chem 257:7262–7268

    PubMed  CAS  Google Scholar 

  • Wun TC, Schleuning D, Reich E (1982b) Isolation and characterization of urokinase from human plasma. J Biol Chem 257:3276–3283

    PubMed  CAS  Google Scholar 

  • Zamarron C, Lijnen HR, Van Hoef B, Collen D (1984) Biological and thrombolytic properties of proenzyme and active forms of human urokinase. 1. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinase obtained from human urine or by recombinant DNA technology. Thromb Haemost 52:19–23

    PubMed  CAS  Google Scholar 

  • Zarich SW, Kowalchuk GJ, Weaver WD, Loscalzo J, Sassower M, Manzo K, Byrnes C, Muller JE, Gurewich V, for the PATENT Study Group (1995) Sequential combination thrombolytic therapy for acute myocardial infarction: results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) Trial. J Am Coll Cardiol 26:374–379

    Article  PubMed  CAS  Google Scholar 

  • Zhu Y, Carmeliet P, Fay WP (1999) Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation 99:3050–3055

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. V. Gurewich
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. FRAT — Hôpital Nestlé 2077, CHUV, CH-1011, Lausanne, Switzerland

    F. Bachmann

  2. Chemin Praz Mandry 20, CH-1052, Le Mont, Switzerland

    F. Bachmann

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Gurewich, V. (2001). Urokinase and Single-Chain Urokinase-Type Plasminogen Activator (Pro-urokinase). In: Bachmann, F. (eds) Fibrinolytics and Antifibrinolytics. Handbook of Experimental Pharmacology, vol 146. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56637-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-56637-0_9

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-63029-3

  • Online ISBN: 978-3-642-56637-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation